Ikarian Capital, LLC Viridian Therapeutics, Inc.\De Transaction History
Ikarian Capital, LLC
- $714 Million
- Q1 2025
A detailed history of Ikarian Capital, LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Ikarian Capital, LLC holds 494,949 shares of VRDN stock, worth $6.72 Million. This represents 0.93% of its overall portfolio holdings.
Number of Shares
494,949
Previous 175,100
182.67%
Holding current value
$6.72 Million
Previous $3.36 Million
98.78%
% of portfolio
0.93%
Previous 0.55%
Shares
3 transactions
Others Institutions Holding VRDN
# of Institutions
189Shares Held
79.6MCall Options Held
92.2KPut Options Held
55.2K-
Deep Track Capital, LP Greenwich, CT5.38MShares$73 Million2.54% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$64.8 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.7MShares$63.8 Million5.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.56MShares$61.9 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$52.7 Million12.64% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $541M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...